9sic
Crystal structure of human Signal Regulatory Protein 2 (SIRP) alpha V2 - Q52A mutant
Structural highlights
Publication Abstract from PubMedThe protein-protein interaction between Signal Regulatory Protein alpha (SIRPalpha) and CD47 is a critical immune checkpoint that enables tumor immune escape, making it a key target for cancer immunotherapy. While antibody-based therapies exist, the development of small-molecule inhibitors has been hindered by the flat, featureless binding interface. Here, we report the discovery of a novel, druggable cryptic pocket within the SIRPalpha D1 domain (the WYF pocket), revealed through a structure-based fragment screening campaign using x-ray crystallography. This pocket, defined by residues Trp38, Tyr50, and Phe74, is only accessible in a conformation that is incompatible with CD47 binding, making it a candidate for structure-based drug design and immune checkpoint inhibitor development. Through a combination of NMR spectroscopy, molecular dynamics simulations, and biophysical assays, we demonstrate that access to this cryptic site is dynamically controlled by a single "gatekeeper" residue, Gln52. The rotameric state of Gln52 dictates a conformational equilibrium between a "closed," state and a ligand-accessible "open" state. We validated this mechanism by engineering SIRPalpha mutants to bias this equilibrium. A Q52F mutation locked the pocket in a closed state, abolishing both CD47 and fragment binding, while Q52A and Q52R mutations biased the protein toward an open state. These "open-biased" mutants not only exhibited decreased affinity for CD47 but also significantly improved binding to small-molecule fragments that inhibit the SIRPalpha-CD47 interaction. This work reveals the intrinsic conformational plasticity of SIRPalpha and establishes a validated structure-based roadmap for a new class of allosteric inhibitors. This 'flexibility-for-inhibition' strategy functions by trapping a non-binding conformation and represents a broadly applicable framework for targeting this and other challenging immune checkpoints. Engineering SIRPalpha conformational plasticity to reveal a cryptic pocket suitable for structure-based drug design.,Storder M, Barelier S, Cordier F, Yacoub T, Ilari L, Barral K, Mahmoodi S, Saez-Ayala M, Combes S, Betzi S, Derviaux C, Ulliana A, Torres F, Rubin J, Roche P, Morelli X, Garcin ED, Miller TW bioRxiv [Preprint]. 2025 Dec 23:2025.12.10.693509. doi: , 10.64898/2025.12.10.693509. PMID:41497624[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||||||
